Ospemifene: A Pill for Menopausal Painful Sex
SaveOspemifene (Osphena) is a once-daily oral pill for moderate-to-severe painful sex after menopause. A selective estrogen receptor modulator, it acts like estrogen on vaginal tissue while behaving differently elsewhere — an option for women avoiding vaginal products. Its main tradeoff is that it can trigger or worsen hot flashes.
Last updated: July 2026
What is ospemifene and how does it work?
Ospemifene is a selective estrogen receptor modulator, or SERM, taken as a single daily tablet. A SERM switches estrogen's signal on in some tissues and off in others; ospemifene turns it on in the vagina, thickening and moisturizing tissue thinned after menopause 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. The Food and Drug Administration approved it for moderate-to-severe painful sex and dryness from the genitourinary syndrome of menopause, which affects up to 1 in 2 postmenopausal women 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG Practice Bulletin 213 identifies genitourinary syndrome of menopause as a common, treatable cause of painful sex and reviews ospemifene among treatment options.. Working from the inside as a pill, it reaches the same tissue that vaginal estrogen treats topically. Its selective action is meant to help vaginal tissue without acting like estrogen everywhere. That design is the reason it fits some women who cannot or prefer not to use local products.
How well does the pill work, and how fast?
Ospemifene improved painful sex and vaginal tissue health compared with placebo in the trials behind its approval, according to menopause society guidance 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. Benefits typically build over about 12 weeks as tissue rebuilds, so it is a steady daily treatment rather than an as-needed remedy 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. Menopause and endocrine guidelines list it among evidence-based options for genitourinary symptoms, alongside vaginal estrogen and prasterone 3Ref 3Stuenkel CA, et al. (Endocrine Society) (2015).Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.The Endocrine Society clinical practice guideline lists ospemifene and other evidence-based options for genitourinary symptoms of menopause and describes SERM class considerations.. Because it is taken by mouth, some women find a pill simpler than applying vaginal estrogen creams or inserts. It treats the genitourinary symptoms of low estrogen, not hot flashes, night sweats, or bone loss. For whole-body menopause symptoms, other treatments remain necessary.
What are the tradeoffs and risks?
The most common side effect of ospemifene is hot flashes, which it can start or worsen — an important contrast with vaginal estrogen, which does not 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. As an estrogen-like agent, it carries the class cautions of systemic hormone exposure, including a small risk of blood clots, and it is generally avoided in women with certain cancer or clotting histories 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. A boxed warning, shared with other estrogen products, reflects these class concerns rather than unique dangers of this pill 3Ref 3Stuenkel CA, et al. (Endocrine Society) (2015).Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline.The Endocrine Society clinical practice guideline lists ospemifene and other evidence-based options for genitourinary symptoms of menopause and describes SERM class considerations.. Vaginal moisturizers and low-dose vaginal estrogen can ease symptoms with a different risk profile and pair well with any treatment 4Ref 4Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.This Cochrane review found low-dose vaginal estrogen relieves vaginal atrophy symptoms more effectively than placebo, supporting local therapy as a comparator with a different risk profile.. Because it is systemic, women with a history of hormone-sensitive cancer weigh it especially carefully with their care team 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. These tradeoffs shape who is a good candidate.
Who is ospemifene right for across midlife?
Ospemifene is meant for postmenopausal women whose main problem is moderate-to-severe painful sex or dryness. Menopause usually occurs between ages 45 and 55, and genitourinary symptoms often begin in the perimenopausal transition and intensify afterward 5Ref 5World Health Organization (2024).Menopause (fact sheet).The WHO menopause fact sheet states menopause typically occurs between ages 45 and 55, with symptoms often beginning in the perimenopausal transition.. It is not used before menopause or during pregnancy, and its role in younger low-estrogen states, such as during breastfeeding, is not established 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. A woman already bothered by frequent hot flashes may prefer vaginal estrogen or prasterone, since the pill can add to that symptom 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. Someone who dislikes vaginal products, by contrast, may welcome a daily tablet. Fit depends on symptom pattern, other health conditions, and personal preference, revisited as those change over time.
When to discuss ospemifene with a clinician
A clinician can judge whether ospemifene fits your symptoms, health history, and preferences better than a vaginal option. A personal history of blood clots, stroke, or hormone-sensitive cancer, or unexplained vaginal bleeding, is a reason to seek clinician review before starting any estrogen-like treatment 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. A gynecologist or menopause-focused clinician can compare the pill with vaginal estrogen and other therapies and monitor how well it works over the first 3 months 2Ref 2American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG Practice Bulletin 213 identifies genitourinary syndrome of menopause as a common, treatable cause of painful sex and reviews ospemifene among treatment options.. Because roughly 50% of postmenopausal women have genitourinary symptoms yet many stay silent, naming the problem is the first move toward relief 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.. Gale can help you prepare for that conversation and the questions worth asking.
Common questions
Related
Sexual health
Prasterone (Vaginal DHEA): How It HelpsSexual health
Testosterone for Low Desire: What Evidence SupportsSexual health
Getting Help for Painful Sex: Your First Steps
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
Ospemifene safety signals
- —A personal history of blood clots, stroke, or hormone-sensitive cancer is a reason to review ospemifene with a clinician before use
- —New or unexplained vaginal bleeding is a reason to seek prompt clinician evaluation
- —Worsening or intolerable hot flashes on the pill are a reason to seek clinician review of the treatment
- —Sudden one-sided leg swelling, chest pain, or trouble breathing can signal a blood clot and is a reason to seek emergency care
Sudden chest pain, trouble breathing, or one-sided leg swelling can signal a blood clot — call 911 or go to the nearest emergency room right away.
This article is general health education, not medical advice. Whether ospemifene is right for you is a decision to make with a gynecologist or menopause-focused clinician who knows your health history.
References
- 1.The North American Menopause Society (Menopause Society) (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000001609 ✓The North American Menopause Society 2020 genitourinary syndrome of menopause position statement describes ospemifene as an FDA-approved oral SERM for moderate-to-severe dyspareunia that improves symptoms versus placebo, notes hot flashes as a common side effect and a class venous-thromboembolism caution, and advises caution in hormone-sensitive cancer.
- 2.American College of Obstetricians and Gynecologists (2019). Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003324 ✓ACOG Practice Bulletin 213 identifies genitourinary syndrome of menopause as a common, treatable cause of painful sex and reviews ospemifene among treatment options.
- 3.Stuenkel CA, et al. (Endocrine Society) (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. doi:10.1210/jc.2015-2236 ✓The Endocrine Society clinical practice guideline lists ospemifene and other evidence-based options for genitourinary symptoms of menopause and describes SERM class considerations.
- 4.Lethaby A, Ayeleke RO, Roberts H (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001500.pub3 ✓This Cochrane review found low-dose vaginal estrogen relieves vaginal atrophy symptoms more effectively than placebo, supporting local therapy as a comparator with a different risk profile.
- 5.World Health Organization (2024). Menopause (fact sheet). World Health Organization (WHO). link ✓The WHO menopause fact sheet states menopause typically occurs between ages 45 and 55, with symptoms often beginning in the perimenopausal transition.
5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy